These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7855695)

  • 21. The use of recombinant human erythropoietin (rHuEpo) in humans.
    Adamson JW; Eschbach JW
    Cancer Surv; 1990; 9(1):157-67. PubMed ID: 2276112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin.
    Musto P; Matera R; Minervini MM; Checchia-de Ambrosio C; Bodenizza C; Falcone A; Carotenuto M
    Haematologica; 1994; 79(3):265-8. PubMed ID: 7926977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study.
    Tatarelli C; Piccioni AL; Maurillo L; Naso V; Battistini R; D'Andrea M; Criscuolo M; Nobile C; Villivà N; Mancini S; Neri B; Breccia M; Fenu S; Buccisano F; Voso MT; Latagliata R; Aloe Spiriti MA
    Ann Hematol; 2014 Aug; 93(8):1413-20. PubMed ID: 24647684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
    Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
    Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
    Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Recombinant human erythropoietin in the treatment of anemia associated with lymphoproliferative diseases--chronic lymphadenosis and multiple myeloma].
    Haber J; Spicka I; Petruzelka L; Kolesková E; Straub J; Jonásová A; Pospísilová B
    Vnitr Lek; 1996 Apr; 42(4):262-7. PubMed ID: 8693713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
    Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
    Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficacy of recombinant human erythropoietin (rhuEPO) in treatment of anemia in patients with myelodysplastic syndrome].
    Wiecek A; Chudek J; Nieszporek T; Kokot F
    Pol Arch Med Wewn; 1992 Dec; 88(6):451-7. PubMed ID: 1300567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Retrospective analysis of hemotherapy support in 226 cases of myelodysplastic syndromes].
    Rubio-Félix D; Franco E; Giraldo P; Gimeno J; Cuesta I; Giralt M
    Sangre (Barc); 1994 Apr; 39(2):117-20. PubMed ID: 8059289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Phase II clinical study of recombinant human erythropoietin on the anemia of myelodysplastic syndrome].
    Urabe A; Mizoguchi H; Takaku F; Miyazaki T; Yachi A; Niitsu Y; Miura Y; Mutoh Y; Fujioka S; Nomura T
    Rinsho Ketsueki; 1993 Aug; 34(8):928-36. PubMed ID: 8411647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes.
    Stenke L; Wallvik J; Celsing F; Hast R
    Leukemia; 1993 Sep; 7(9):1324-7. PubMed ID: 8371582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Haematopoietic growth factors in the treatment of myelodysplastic syndromes.
    Cazzola M
    Forum (Genova); 1999; 9(1):49-57. PubMed ID: 10101210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin.
    Bowen D; Culligan D; Jacobs A
    Br J Haematol; 1991 Mar; 77(3):419-23. PubMed ID: 2012769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy.
    Cazzola M; Ponchio L; Pedrotti C; Farina G; Cerani P; Lucotti C; Novella A; Rovati A; Bergamaschi G; Beguin Y
    Haematologica; 1996; 81(5):434-41. PubMed ID: 8952157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of recombinant human erythropoietin treatment on cortisol responses to insulin-induced hypoglycemia in CAPD patients.
    Díez JJ; Iglesias P; Sastre J; Gómez-Pan A; Selgas R; Romero JR; Méndez J
    Adv Perit Dial; 1993; 9():336-41. PubMed ID: 8105958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants.
    Locatelli F; Zecca M; Pedrazzoli P; Prete L; Quaglini S; Comoli P; De Stefano P; Beguin Y; Robustelli della Cuna G; Severi F
    Bone Marrow Transplant; 1994 Apr; 13(4):403-10. PubMed ID: 8019464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature.
    Cervantes F; Alvarez-Larrán A; Hernández-Boluda JC; Sureda A; Torrebadell M; Montserrat E
    Br J Haematol; 2004 Nov; 127(4):399-403. PubMed ID: 15521916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Sequential treatment with granulocyte-colony stimulating factor (GCSF) and human recombinant erythropoietin (rH-EPO) in anemia of a patient with myelodysplastic syndrome and high blood transfusion requirements)].
    Borbolla-Escoboza JR; González-Avante CM; López-Hernández MA; Flores-Chapa JD; Collados-Larumbe MT
    Gac Med Mex; 1997; 133(4):355-9. PubMed ID: 9410796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes.
    Voulgari PV; Hatzimichael EC; Tsiara S; Tzallas C; Drosos AA; Bourantas KL
    Eur J Haematol; 2001 Jan; 66(1):31-6. PubMed ID: 11168505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
    Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
    Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.